Transgene Biotek will sell one of its bio-generic products 'Erythropoietin', to Tss Export GmbH for a total consideration of $5 million (over Rs 26 crore). The management of Transgene has formalised the sale of technology of one of its bio-generic products, Erythropoietin to 'Tss Export GmbH FZE' for a total consideration of $5 million.

Erythropoietin is a hormone produced by the kidney that promotes the formation of red blood cells in the bone marrow. This sale of technology is expected to be completed during a period of approximately 5-6 months. With the market for Erythropoietin set to become very competitive, the management of Transgene has decided to monetise some of the dormant technologies through either out-licensing or strategic partnerships within and outside India. The company had earlier out-licensed two of its technologies - a recombinant Hepatitis B Vaccine to one of the largest vaccine producers in the world, and more recently Orlistat to one of the biggest Indian pharma companies with a significant presence on the global arena.

Transgene Biotek Share Price

3.08 0.08 (2.67%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Apollo Hospital Ent. 7189.25
Max Healthcare Inst 1097.95
Narayana Hrudayalay 1916.45
Aster DM Healthcare 635.10
Global Health 1163.75
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×